Literature DB >> 333308

Catecholamine and octopamine concentrations in brains of patients with Reye syndrome.

K G Lloyd, L Davidson, K Price, H J McClung, D G Gall.   

Abstract

Dopamine, norepinephrine, and octopamine levels were estimated in regions of brains obtained postmortem from children who died with Reye syndrome and from age-matched controls. Hypothalamic norepinephrine levels were greatly decreased (to 30 percent of control, p less than 0.02) and octopamine levels were increased (to 700 percent of control, p less than 0.01). Levodopa had little effect on the physiologic condition of the patients. However, CNS dopamine and homovanillic concentrations were not elevated by levodopa, indicating that in the present cases levodopa was not metabolized to its catecholamine products. The findings indicate that the encephalopathy of Reye syndrome (as in other types of hepatic coma) may be linked to the presence of false transmitters in the brain and that levodopa is a rational therapy if administered before irreversible CNS changes occur.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 333308     DOI: 10.1212/wnl.27.10.985

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  5 in total

1.  Arrhythmias and ischemia-like ECG changes in Reye's syndrome.

Authors:  A Sarti; F Cecchi; A Manetti; P Busoni
Journal:  Intensive Care Med       Date:  1996-01       Impact factor: 17.440

2.  Plasma catecholamines in hepatic coma and liver cirrhosis: role of octopamine.

Authors:  H Hörtnagl; H Lochs; G Kleinberger; J M Hackl; A F Hammerle; H Binder; F Wewalka
Journal:  Klin Wochenschr       Date:  1981-10-15

3.  Aflatoxin B1 alters central and systemic tryptophan and tyrosine metabolism: influence of immunomodulatory drugs.

Authors:  L B Weekley
Journal:  Metab Brain Dis       Date:  1991-03       Impact factor: 3.584

Review 4.  Reye's syndrome: a clinical review.

Authors:  J F Crocker; P C Bagnell
Journal:  Can Med Assoc J       Date:  1981-02-15       Impact factor: 8.262

5.  Evidence for central hypertyraminemia in hepatic encephalopathy.

Authors:  B A Faraj; V M Camp; J D Ansley; J Scott; F M Ali; E J Malveaux
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.